

## 1 June 2020

## **Issue of New Shares**

Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that, further to the announcement dated 27 May 2020, the Company has issued 50,000 shares as commission to a financial advisor for organizing the Convertible Notes.

## Notice given under section 708A(5) of the Corporations Act 2001 (Cth)

This notice is given by the Company under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue of 50,000 fully paid shares by the Company without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, the Company has complied with:

- the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
   and
- 2. section 674 of the Corporations Act.

There is no excluded information as at the date of this notice, for the purposes of Section 708A (7) and (8) of the Corporations Act.

-End-

## **About Beroni Group Limited**

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit <a href="https://www.beronigroup.com">www.beronigroup.com</a>.

Mr Jacky Zhang Executive Chairman Tel: +86 1851 6931 911

E: jacky.zhang@beronigroup.com

Mr Peter Wong
Executive Director & CFO
Tel: +61 423 727 580

E: peter.wong@beronigroup.com